SCHEMBL5506735

SCHEMBL5506735

O=C(O)c1ccc(CN(Cc2ccc(C(F)(F)P(=O)(O)O)cc2)c2nnc(-c3cccc(Oc4ccccc4)c3)o2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.43
PTPN2 P17706 1/20 0.42
PTPRB P23467 1/20 0.42
PTPN6 P29350 1/20 0.42
PTPN11 Q06124 1/20 0.42
PTPN5 P54829 2/20 0.42
PTGES O14684 1/20 0.41
ALOX5 P09917 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LPAR1 Q92633 2/20 0.39
LPAR5 Q9H1C0 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5502775 0.92 PTPN1 (0.44) PTPN1PTPN2PTPRBPTPN6PTPN11
SCHEMBL5502717 0.85 PTGES (0.41) PTGESALOX5MEN1KMT2ALPAR1
SCHEMBL5508633 0.84 PTPN5 (0.43) PTPN1PTPN2PTPRBPTPN6PTPN11
SCHEMBL6154058 0.83 PTPN1 (0.41) PTPN1PTPN2PTPRBPTPN6PTPN11
SCHEMBL5505414 0.80 PTPN5 (0.40) PTPN1PTPN2PTPRBPTPN6PTPN11
SCHEMBL5508244 0.77 PTPN5 (0.42) PTPN1PTPN2PTPRBPTPN6PTPN11
SCHEMBL5502778 0.77 CETP (0.41) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL4958080 0.76 PTPN1 (0.45) PTPN1PTPN2PTPRBPTPN6PTPN11
SCHEMBL12171782 0.74 NPC1 (0.70) PTPN1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5505306 0.73 PTPN1 (0.39) PTPN1PTPN2PTPN5PTGESALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP claimed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US claimed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO claimed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases PTPRO, PTPRG, PTPN1 PTPN1 3/4885PTPN2 24/4885PTPRB 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.